


What we claim is:

1. A compound of matter having the formula:



- 5 wherein R^1 is $-\text{CH}_2\text{OH}$, $-\text{C}(=\text{O})\text{NR}^5\text{R}^6$;

R^2 is selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO_2 , heterocyclyl, aryl, heteroaryl, CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{SO}_2\text{NR}^{20}\text{COR}^{22}$, $\text{SO}_2\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{SO}_2\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{N}(\text{R}^{20})_2\text{NR}^{20}\text{COR}^{22}$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{C}(\text{NR}^{20})\text{NHR}^{23}$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{CONR}^{20}\text{SO}_2\text{R}^{22}$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, $\text{SO}_2\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{OCONR}^{20}\text{SO}_2\text{R}^{22}$, $\text{OC}(\text{O})\text{R}^{20}$, $\text{C}(\text{O})\text{OCH}_2\text{OC}(\text{O})\text{R}^{20}$, and $\text{OCON}(\text{R}^{20})_2$ and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, NO_2 , alkyl, CF_3 , amino, mono- or di- alkylamino, alkyl or aryl or heteroaryl amide, NCOR^{22} , $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{OC}(\text{O})\text{R}^{20}$, $\text{OC}(\text{O})\text{N}(\text{R}^{20})_2$, SR^{20} , $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, CN , and OR^{20} ;

R^3 , R^4 are each individually selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, and heteroaryl, halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{SO}_2\text{NR}^{20}\text{COR}^{22}$, $\text{SO}_2\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{SO}_2\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{N}(\text{R}^{20})_2\text{NR}^{20}\text{COR}^{22}$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{C}(\text{NR}^{20})\text{NHR}^{23}$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{CONR}^{20}\text{SO}_2\text{R}^{22}$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, $\text{SO}_2\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{OCONR}^{20}\text{SO}_2\text{R}^{22}$, $\text{OC}(\text{O})\text{R}^{20}$, $\text{C}(\text{O})\text{OCH}_2\text{OC}(\text{O})\text{R}^{20}$, and $\text{OCON}(\text{R}^{20})_2$ wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO_2 , heterocyclyl, aryl, heteroaryl, CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{SO}_2\text{NR}^{20}\text{COR}^{22}$,

$\text{SO}_2\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{SO}_2\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{N}(\text{R}^{20})_2$, $\text{NR}^{20}\text{COR}^{22}$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$,
 $\text{NR}^{20}\text{C}(\text{NR}^{20})\text{NHR}^{23}$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{CONR}^{20}\text{SO}_2\text{R}^{22}$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$,
 $\text{SO}_2\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{OCONR}^{20}\text{SO}_2\text{R}^{22}$, $\text{OC}(\text{O})\text{R}^{20}$, $\text{C}(\text{O})\text{OCH}_2\text{OC}(\text{O})\text{R}^{20}$, and $\text{OCON}(\text{R}^{20})_2$ and
 wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted
 5 with halo, NO_2 , alkyl, CF_3 , amino, mono- or di- alkylamino, alkyl or aryl or heteroaryl amide,
 NCOR^{22} , $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{OC}(\text{O})\text{R}^{20}$, $\text{OC}(\text{O})\text{N}(\text{R}^{20})_2$,
 SR^{20} , $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, CN , and OR^{20} ;

R^5 and R^6 are each individually selected from H, C_{1-15} alkyl with from 1 to 2
 substituents independently selected from the group consisting of halo, NO_2 , heterocyclyl, aryl,
 10 heteroaryl, CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{SO}_2\text{NR}^{20}\text{COR}^{22}$,
 $\text{SO}_2\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{SO}_2\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{N}(\text{R}^{20})_2$, $\text{NR}^{20}\text{COR}^{22}$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$,
 $\text{NR}^{20}\text{C}(\text{NR}^{20})\text{NHR}^{23}$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{CONR}^{20}\text{SO}_2\text{R}^{22}$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$,
 $\text{SO}_2\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{OCONR}^{20}\text{SO}_2\text{R}^{22}$, $\text{OC}(\text{O})\text{R}^{20}$, $\text{C}(\text{O})\text{OCH}_2\text{OC}(\text{O})\text{R}^{20}$, and $\text{OCON}(\text{R}^{20})_2$, and
 wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted
 15 with halo, NO_2 , alkyl, CF_3 , amino, mono- or di- alkylamino, alkyl or aryl or heteroaryl amide,
 NCOR^{22} , $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, $\text{OC}(\text{O})\text{R}^{20}$, $\text{OC}(\text{O})\text{N}(\text{R}^{20})_2$,
 SR^{20} , $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, CN , and OR^{20} ;

R^{20} is selected from the group consisting of H, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl,
 heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and
 20 heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently
 selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN , $\text{O}-\text{C}_{1-6}$
 alkyl, CF_3 , aryl, and heteroaryl; and

R^{22} is a member selected from the group consisting of C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15}
 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl,
 25 aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents
 independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl
 amide, CN , $\text{O}-\text{C}_{1-6}$ alkyl, CF_3 , and heteroaryl wherein, when R^1 is CH_2OH , and R^3 is H and R^4
 is H, and the pyrazole ring is attached through C^4 , then R^2 is not H.

2. The compound of claim 1 wherein R^2 is selected from the group consisting of
 30 hydrogen, C_{1-15} alkyl, C_{2-15} alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl,
 alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1
 to 3 substituents independently selected from the group consisting of halo, NO_2 , heterocyclyl,
 aryl, heteroaryl, CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, COR^{20} , CO_2R^{20} ,
 $\text{CON}(\text{R}^{20})_2$, and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is

optionally substituted with halo, alkyl, CF₃, CN, and OR²⁰;

R³ and R⁴ are each individually selected from the group consisting of hydrogen, C₁₋₁₅ alkyl, C₂₋₁₅ alkynyl, heterocyclyl, aryl, heteroaryl, halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, COR²⁰, CO₂R²⁰, CON(R²⁰)₂, wherein the alkyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO₂, heterocyclyl, aryl, heteroaryl, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, COR²⁰, CO₂R²⁰, CON(R²⁰)₂, and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, alkyl, CF₃, CN, and OR²⁰;

R⁵ and R⁶ are each individually selected from H, and C₁₋₁₅ alkyl having from 1 to 2 substituents independently selected from the group consisting of aryl, heteroaryl, CF₃, OR²⁰, and wherein each optional heteroaryl, and aryl substituent is further optionally substituted with halo, alkyl, and CF₃;

R²⁰ is a member selected from the group consisting of H, C₁₋₆ alkyl, aryl, and heteroaryl; and

R²² is a member selected from the group consisting of C₁₋₆ alkyl, aryl, and heteroaryl, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from halo, alkyl, CN, O-C₁₋₆ alkyl, and CF₃.

3. The compound of claim 1 wherein R² is selected from the group consisting of hydrogen, C₁₋₁₅ alkyl, C₂₋₁₅ aryl, and heteroaryl, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, CF₃, CN, OR²⁰, SR²⁰, S(O)R²², CO₂R²⁰, CON(R²⁰)₂, and wherein each optional heteroaryl, and aryl substituent is optionally substituted with halo, alkyl, CF₃, CN, and OR²⁰;

R³ and R⁴ are each individually selected from the group consisting of hydrogen, C₁₋₁₅ alkyl, C₂₋₁₅ aryl, heteroaryl, halo, CF₃, CN, OR²⁰, SR²⁰, S(O)R²², CO₂R²⁰, and CON(R²⁰)₂, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, CF₃, CN, OR²⁰, SR²⁰, S(O)R²², CO₂R²⁰, and CON(R²⁰)₂, and wherein each optional heteroaryl, and aryl substituent is optionally substituted with halo, alkyl, CF₃, CN, and OR²⁰;

R⁵ and R⁶ are each individually selected from H, and C₁₋₁₅ alkyl having from 1 to 2 substituents selected from CF₃;

R²⁰ is selected from H, and C₁₋₆; and

R²² is C₁₋₆ alkyl.

4. The compound of claim 1 wherein R² is independently selected from the group consisting of hydrogen, C₁₋₁₅ alkyl, C₂₋₁₅ aryl, and heteroaryl, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, heteroaryl, CF₃, CN, OR²⁰, CO₂R²⁰, and CON(R²⁰)₂, and wherein each optional heteroaryl, and aryl substituent is optionally substituted with halo, alkyl, CF₃, and CN;

R³ and R⁴ are each individually selected from the group consisting of hydrogen, C₁₋₁₅ alkyl, C₂₋₁₅ aryl, heteroaryl, halo, CF₃, CN, OR²⁰, CO₂R²⁰, and CON(R²⁰)₂, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, heteroaryl, CF₃, CN, OR²⁰, CO₂R²⁰, and CON(R²⁰)₂, and wherein each optional heteroaryl, and aryl substituent is optionally substituted with halo, alkyl, CF₃ or CN;

R⁵ and R⁶ are each individually selected from H, and C₁₋₁₅ alkyl;

R^{20} is selected from H, and C_{1-6} ; and

R^{22} is C_{1-6} alkyl.


5. The compound of claim 1 wherein R² is independently selected from the group consisting of hydrogen, C₁₋₁₅ alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR²⁰, aryl, CF₃, CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF₃ or CN;

R³ and R⁴ are each individually selected from the group consisting of hydrogen, C₁₋₁₅ alkyl, aryl, halo, CF₃, and CN, wherein the alkyl, and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, CF₃, CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF₃, or CN;


R⁵ and R⁶ are each individually selected from H, and C₁₋₁₅ alkyl; and

R^{20} is selected from H, and C_{1-6} .


6. The compound of claims 1 or 2 or 3 or 4 or 5 having the following formula wherein the point of attachment of the pyrazole ring is C-4.



7. The compound of claims 1 or 2 or 3 or 4 or 5 having the following formula wherein the point of attachment of the pyrazole ring is C-3.



8. The compound of claims 1 or 2 or 3 or 4 or 5 having the following formula wherein the point of attachment of the pyrazole ring is C-5.



9. The compound of claims 6 or 7 or 8 wherein $R^1 = \text{CH}_2\text{OH}$;

10. The compound of claim 6 wherein R^1 is $-\text{CH}_2\text{OH}$;

R^2 is independently selected from the group consisting of hydrogen, C_{1-10} alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR^{20} , aryl, CF_3 , and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 , and CN;

R^3 and R^4 are each individually- selected from the group consisting of hydrogen, C_{1-15} alkyl, aryl, halo, CF_3 , and CN, wherein the alkyl, and aryl substituents are optionally substituted with a substituent independently selected from the group consisting of halo, CF_3 , and CN; and

R^{20} is selected from H, and C_{1-6} alkyl;

11. The compound of claim 6 wherein R^1 is $-\text{CH}_2\text{OH}$;

R^2 is independently selected from the group consisting of hydrogen, C_{1-8} alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR^{20} , aryl, CF_3 , and

CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF₃, and CN;

R³ and R⁴ are each individually selected from the group consisting of hydrogen, C₁₋₃ alkyl, aryl, halo, CF₃, CN; and

5 R²⁰ is selected from H, and C₁₋₆ alkyl.

12. The compound of claim 6 wherein R¹ is -CH₂OH;

R² is independently selected from the group consisting of hydrogen, C₁₋₈ alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR²⁰, aryl, CF₃, and
10 CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF₃, and CN;

R³ and R⁴ are each individually selected from the group consisting of hydrogen, methyl, and halo; and

R²⁰ is selected from H, and C₁₋₆;

15 13. The compound of claim 6 wherein R¹ is -CH₂OH;

R² is independently selected from the group consisting of hydrogen, C₁₋₈ alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, aryl, CF₃, and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF₃, and CN; and

20 R³ and R⁴ are each individually selected from the group consisting of hydrogen, and methyl.

14. The compound of claim 6 wherein R¹ is -CH₂OH;

R² is selected from the group consisting of hydrogen, and C₁₋₈ alkyl that is optionally substituted with 1 substituent selected from the group consisting of aryl, CF₃, and CN, and
25 wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF₃, and CN; and

R³ and R⁴ are each individually selected from the group consisting of hydrogen, and methyl.

15. The compound of claim 6 wherein R¹ is -CH₂OH;

30 R² is selected from the group consisting of hydrogen, and C₁₋₈ alkyl that is optionally substituted with one aryl substituent that is optionally substituted with halo, alkyl, CF₃, and CN; and

R³ and R⁴ are each hydrogen.

16. The compound of claim 6 wherein R¹ is -CH₂OH;

R^2 is selected from the group consisting of hydrogen, and C_{1-6} alkyl that is optionally substituted with aryl that is optionally substituted with alkyl; and

R^3 and R^4 are each hydrogen.

17. The compound of claim 7 wherein R^1 is $-\text{CH}_2\text{OH}$;

5 R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with 1 substituent selected from the group consisting of aryl, CF_3 , and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are each individually selected from hydrogen, and methyl.

10 18. The compound of claim 7 wherein R^1 is $-\text{CH}_2\text{OH}$;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with 1 substituent selected from the group consisting of aryl, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are each hydrogen.

15 19. The compound of claim 7 wherein R^1 is $-\text{CH}_2\text{OH}$;

R^2 is selected from the group consisting of hydrogen, and C_{1-6} alkyl that is optionally substituted with aryl that is optionally substituted with alkyl; and

R^3 and R^4 are each hydrogen.

20. The compound of claim 8 wherein R^1 is $-\text{CH}_2\text{OH}$;

20 R^2 is selected from the group consisting of hydrogen, and C_{1-6} alkyl;

R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, and aryl, wherein the alkyl, and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, CF_3 , and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN; and

25 R^4 is selected from the group consisting of hydrogen and C_{1-6} alkyl.

21. The compound of claim 8 wherein R^1 is $-\text{CH}_2\text{OH}$;

R^2 is selected from the group consisting of hydrogen, and methyl;

R^3 and R^4 are each independently selected from the group consisting of hydrogen, and C_{1-6} alkyl, that is optionally substituted with aryl that is optionally substituted with alkyl; and

30 R^4 is selected from hydrogen and methyl.

22. The compound of claim 6 wherein R^1 is $-\text{CONHEt}$;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with 1 substituent selected from the group consisting of aryl, CF_3 , and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN;

and

R³ and R⁴ are each individually selected from the group consisting of hydrogen, and methyl.

23. The compound of claim 6 wherein R¹ is -CONHEt;

5 R² is selected from the group consisting of hydrogen, and C₁₋₈ alkyl that is optionally substituted with 1 aryl substituent of aryl, that is optionally substituted with halo, alkyl, CF₃, and CN; and

R³ and R⁴ are each hydrogen.

24. The compound of claim 6 wherein R¹ is -CONHEt;

10 R² is selected from the group consisting of hydrogen, and C₁₋₆ alkyl that is optionally substituted with aryl that is optionally substituted with alkyl; and

R³ and R⁴ are hydrogen.

25. The compound of claim 7 wherein R¹ is -CONHEt;

15 R² is selected from the group consisting of hydrogen, and C₁₋₈ that is optionally substituted with 1 aryl substituent that is optionally substituted with halo, alkyl, CF₃, and CN; and

R³ and R⁴ are hydrogen.

26. The compound of claim 7 wherein R¹ is -CONHEt;

20 R² is independently selected from the group consisting of hydrogen, and C₁₋₆ alkyl that is optionally substituted with aryl that is optionally substituted with alkyl; and

R³ and R⁴ are each hydrogen.

27. The compound of claim 8 wherein R¹ is -CONHEt; and

R² is selected from hydrogen, and methyl;

25 R³ and R⁴ are each individually selected from the group consisting of hydrogen, and C₁₋₆ alkyl, wherein the alkyl, is optionally substituted with aryl that is optionally substituted with alkyl; and

R⁴ is selected from hydrogen and methyl.

28. The compound of claim 1 wherein the compound is selected from (4S,2R,3R,5R)-2-{6-amino-2-[1-benzylpyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol,

30 (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9yl]-5-(hydroxymethyl)oxolane-

3,4-diol, (4S,2R,3R,5R)-2-[6-amino-2-(1-methylpyrazol-4-yl)purin-9-yl]-5-

(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(methylethyl)pyrazol-4-

yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(3-phenylpropyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(4-t-butylbenzyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-(6-amino-2-pyrazol-4-ylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-pent-4-enylpyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-decylpyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(cyclohexylmethyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(2-phenylethyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(3-cyclohexylpropyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(2-cyclohexylethyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, and mixtures thereof.

29. A method for stimulating coronary vasodilatation in a mammal by administering to the mammal a therapeutically effective amount of a compound of claim 1 that is sufficient to stress the heart and induce a coronary steal situation for the purposes of imaging the heart.

30. The method of claim 25 wherein the therapeutically effective amount ranges from about 0.01 to about 100 mg/kg weight of the mammal.

31. The method of claim 29 wherein the mammal is a human.

32. A pharmaceutical composition of matter comprising the compound of claim 1 and one or more pharmaceutical excipients.

33. The pharmaceutical composition of matter of claim 32 wherein the pharmaceutical composition is in the form of a solution.

34. The pharmaceutical composition of matter of claim 32 wherein the composition is useful as an anti-inflammatory, in adjunctive therapy with angioplasty, as a platelet aggregation inhibitor, and as an inhibitor of platelet and neutrophil activation.